Will Medical Management of Benign Prostatic Hyperplasia Result in Better or Worse Sexual Function in Men?

Yi-Sheng Huang

Research output: Contribution to journalReview article

1 Citation (Scopus)

Abstract

Urinary symptoms of benign prostatic hyperplasia (BPH) may affect sexual function, considered by patients themselves to be one of the most important aspects of the disease. Though lack of consensus on the underlying mechanism involved, some hypothesis are accounted for this association, such as autonomic hyperactivity, decreased nitric oxide (NO) production in the prostate and penile cavernous muscle, as well as pelvic atherosclerosis and endothelial dysfunction.Although medical treatment with α-blockers and/or 5α-reductase inhibitors are the mainstays of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS), there are some contradictory bias on the effect of sexual function either erectile or ejaculatory function.α-blocker is currently recommended as a first line treatment of BPH. Since it will reduce the sympathetic overstimulation of prostate, it may also affect the similar pathway in penis. It has been suggested that α-blockers may improve sexual function in patients with BPH. However, among α-blockers, tamsulosin is associated with an increased risk of ejaculation disorders. Long-term use of 5α-reductase inhibitors alone or combined with α-blockers will cause reduction of prostate volume and improved the clinical symptoms; however, it may associate with sexual problems, especially ejaculation disorders.Based on the already published data, the effect of α-blockers and 5α-reductase inhibitors on the sexual function will be reviewed. Moreover, this may reinforce physicians to manage appropriately these two highly prevalent and bothersome conditions.

Original languageEnglish
Pages (from-to)14-18
Number of pages5
JournalUrological Science
Volume22
Issue number1
DOIs
Publication statusPublished - Mar 2011

Fingerprint

Prostatic Hyperplasia
Prostate
Oxidoreductases
Ejaculation
tamsulosin
Lower Urinary Tract Symptoms
Penis
Atherosclerosis
Nitric Oxide
Physicians
Muscles
Therapeutics

Keywords

  • α-blocker
  • 5α-reductase inhibitor
  • Benign prostatic hyperplasia
  • Ejaculation
  • Erectile dysfunction

ASJC Scopus subject areas

  • Urology

Cite this

Will Medical Management of Benign Prostatic Hyperplasia Result in Better or Worse Sexual Function in Men? / Huang, Yi-Sheng.

In: Urological Science, Vol. 22, No. 1, 03.2011, p. 14-18.

Research output: Contribution to journalReview article

@article{60242e2edc234c4698907a14717219c8,
title = "Will Medical Management of Benign Prostatic Hyperplasia Result in Better or Worse Sexual Function in Men?",
abstract = "Urinary symptoms of benign prostatic hyperplasia (BPH) may affect sexual function, considered by patients themselves to be one of the most important aspects of the disease. Though lack of consensus on the underlying mechanism involved, some hypothesis are accounted for this association, such as autonomic hyperactivity, decreased nitric oxide (NO) production in the prostate and penile cavernous muscle, as well as pelvic atherosclerosis and endothelial dysfunction.Although medical treatment with α-blockers and/or 5α-reductase inhibitors are the mainstays of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS), there are some contradictory bias on the effect of sexual function either erectile or ejaculatory function.α-blocker is currently recommended as a first line treatment of BPH. Since it will reduce the sympathetic overstimulation of prostate, it may also affect the similar pathway in penis. It has been suggested that α-blockers may improve sexual function in patients with BPH. However, among α-blockers, tamsulosin is associated with an increased risk of ejaculation disorders. Long-term use of 5α-reductase inhibitors alone or combined with α-blockers will cause reduction of prostate volume and improved the clinical symptoms; however, it may associate with sexual problems, especially ejaculation disorders.Based on the already published data, the effect of α-blockers and 5α-reductase inhibitors on the sexual function will be reviewed. Moreover, this may reinforce physicians to manage appropriately these two highly prevalent and bothersome conditions.",
keywords = "α-blocker, 5α-reductase inhibitor, Benign prostatic hyperplasia, Ejaculation, Erectile dysfunction",
author = "Yi-Sheng Huang",
year = "2011",
month = "3",
doi = "10.1016/S1879-5226(11)60003-1",
language = "English",
volume = "22",
pages = "14--18",
journal = "Urological Science",
issn = "1879-5226",
publisher = "Elsevier",
number = "1",

}

TY - JOUR

T1 - Will Medical Management of Benign Prostatic Hyperplasia Result in Better or Worse Sexual Function in Men?

AU - Huang, Yi-Sheng

PY - 2011/3

Y1 - 2011/3

N2 - Urinary symptoms of benign prostatic hyperplasia (BPH) may affect sexual function, considered by patients themselves to be one of the most important aspects of the disease. Though lack of consensus on the underlying mechanism involved, some hypothesis are accounted for this association, such as autonomic hyperactivity, decreased nitric oxide (NO) production in the prostate and penile cavernous muscle, as well as pelvic atherosclerosis and endothelial dysfunction.Although medical treatment with α-blockers and/or 5α-reductase inhibitors are the mainstays of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS), there are some contradictory bias on the effect of sexual function either erectile or ejaculatory function.α-blocker is currently recommended as a first line treatment of BPH. Since it will reduce the sympathetic overstimulation of prostate, it may also affect the similar pathway in penis. It has been suggested that α-blockers may improve sexual function in patients with BPH. However, among α-blockers, tamsulosin is associated with an increased risk of ejaculation disorders. Long-term use of 5α-reductase inhibitors alone or combined with α-blockers will cause reduction of prostate volume and improved the clinical symptoms; however, it may associate with sexual problems, especially ejaculation disorders.Based on the already published data, the effect of α-blockers and 5α-reductase inhibitors on the sexual function will be reviewed. Moreover, this may reinforce physicians to manage appropriately these two highly prevalent and bothersome conditions.

AB - Urinary symptoms of benign prostatic hyperplasia (BPH) may affect sexual function, considered by patients themselves to be one of the most important aspects of the disease. Though lack of consensus on the underlying mechanism involved, some hypothesis are accounted for this association, such as autonomic hyperactivity, decreased nitric oxide (NO) production in the prostate and penile cavernous muscle, as well as pelvic atherosclerosis and endothelial dysfunction.Although medical treatment with α-blockers and/or 5α-reductase inhibitors are the mainstays of benign prostatic hyperplasia/lower urinary tract symptoms (BPH/LUTS), there are some contradictory bias on the effect of sexual function either erectile or ejaculatory function.α-blocker is currently recommended as a first line treatment of BPH. Since it will reduce the sympathetic overstimulation of prostate, it may also affect the similar pathway in penis. It has been suggested that α-blockers may improve sexual function in patients with BPH. However, among α-blockers, tamsulosin is associated with an increased risk of ejaculation disorders. Long-term use of 5α-reductase inhibitors alone or combined with α-blockers will cause reduction of prostate volume and improved the clinical symptoms; however, it may associate with sexual problems, especially ejaculation disorders.Based on the already published data, the effect of α-blockers and 5α-reductase inhibitors on the sexual function will be reviewed. Moreover, this may reinforce physicians to manage appropriately these two highly prevalent and bothersome conditions.

KW - α-blocker

KW - 5α-reductase inhibitor

KW - Benign prostatic hyperplasia

KW - Ejaculation

KW - Erectile dysfunction

UR - http://www.scopus.com/inward/record.url?scp=79954477571&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79954477571&partnerID=8YFLogxK

U2 - 10.1016/S1879-5226(11)60003-1

DO - 10.1016/S1879-5226(11)60003-1

M3 - Review article

AN - SCOPUS:79954477571

VL - 22

SP - 14

EP - 18

JO - Urological Science

JF - Urological Science

SN - 1879-5226

IS - 1

ER -